AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie ABBV underwent analysis by 17 analysts ... Allergan added several new products and drugs in aesthetics (including Botox). Market Capitalization Analysis: With a profound presence, the ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...

Mint explains. In May 2024, the DoP received an anonymous complaint alleging AbbVie Healthcare India flew 30 doctors—experts in Botox and Juvederm—to Paris and Monaco. It said the firm treated ...

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

The complaint was that “Abbvie provided travel tickets and hotel ... The doctors were linked with products Botox and Juvederm, the Order said. The complaint was forwarded to the ethics committee ...

Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some ...